Background alzheimers Shape Background alzheimers Shape Background alzheimers Shape
Grants > Assessment of Tandem Repeat Variation in Alzheimer’s Disease Updated On: Jan. 20, 2025
Alzheimer's Disease Research Grant

Assessment of Tandem Repeat Variation in Alzheimer’s Disease

Genomics
a headhsot of Dr. Trujillo

Principal Investigator

Alejandro Martin Trujillo, PhD

Icahn School of Medicine at Mount Sinai

New York, NY, USA

About the Research Project

Program

Alzheimer's Disease Research

Award Type

Standard

Award Amount

$300,000

Active Dates

July 01, 2022 - June 30, 2025

Grant ID

A2022043S

Mentor(s)

Andrew Sharp, Icahn School of Medicine at Mount Sinai

Goals

The goal of this project is to identify novel tandem repeat variants that underlie Alzheimer’s Disease, enhancing our understanding about the genetic architecture of this disease.

Summary

Tandem Repeats (TRs) are stretches of DNA composed of two or more contiguous copies of a sequence arranged in head-to-tail pattern (eg. CAG-CAG-CAG), that, in some cases, gain additional copies and become expanded. Due to technical limitations, TRs are usually untraceable using standard procedures, being largely ignored in standard genetics studies. However, newly bioinformatics tools are now able to screen the whole genome for repeats expansions and TR variants. Using these tools, we will screen the genomes of thousands of AD cases and controls for TR variants that are associated with AD risk.

Unique and Innovative

Despite Tandem Repeats (TR) representing a significant source of genetic variation and the underlying genetic cause of human diseases, primarily neurodegenerative diseases, they represent a largely unexplored aspect of the human genome and thus, an area of research with high probability of uncovering novel findings on AD pathogenesis. The availability of large genome sequencing datasets together with newly developed bioinformatics tools that are able to genotype TRs from whole genome sequencing data, now provide the opportunity to fill this gap and explore the link between TR variation and AD.

Foreseeable Benefits

The screening of the genomes of thousands of individuals, including 16,000 AD cases and 66,000 controls, will likely lead to the identification of novel TR variants that underlie AD, thus improving (i) our understanding of the genetic risk factors and pathways that lead to AD, (ii) diagnoses and genetic counseling in a fraction of AD cases, and (iii) providing a basis for future development of therapies. Furthermore, as a possible direct result of our study an accurate molecular diagnosis can be provided to some patients with unexplained AD, allowing a better health care for these patients.